News
8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

1.7.21
Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

Read more
27.10.20
News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

Read more
3.7.20
Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

Read more